215 related articles for article (PubMed ID: 19007764)
21. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
[TBL] [Abstract][Full Text] [Related]
22. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
[TBL] [Abstract][Full Text] [Related]
23. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
24. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
[TBL] [Abstract][Full Text] [Related]
25. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
26. Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells.
Matsunaga T; Arakaki M; Kamiya T; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2009 Sep; 181(1):52-60. PubMed ID: 19442656
[TBL] [Abstract][Full Text] [Related]
27. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
[TBL] [Abstract][Full Text] [Related]
28. In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
Li C; Zhao Y; Zheng X; Zhang H; Zhang L; Chen Y; Li Q; Hu X
Chem Biol Interact; 2016 Jun; 253():60-5. PubMed ID: 27163852
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
[TBL] [Abstract][Full Text] [Related]
30. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
32. Characterization of homogeneous recombinant rat ovarian 20alpha-hydroxysteroid dehydrogenase: fluorescent properties and inhibition profile.
Ma H; Penning TM
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):853-9. PubMed ID: 10417353
[TBL] [Abstract][Full Text] [Related]
33. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
34. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
35. Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Winkler JD; Penning TM
Bioorg Med Chem Lett; 2011 Mar; 21(5):1464-8. PubMed ID: 21277203
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
[TBL] [Abstract][Full Text] [Related]
37. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
[TBL] [Abstract][Full Text] [Related]
38. Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.
Skarydova L; Hofman J; Chlebek J; Havrankova J; Kosanova K; Skarka A; Hostalkova A; Plucha T; Cahlikova L; Wsol V
J Steroid Biochem Mol Biol; 2014 Sep; 143():250-8. PubMed ID: 24769118
[TBL] [Abstract][Full Text] [Related]
39. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
